7 research outputs found
Physiological maps and chemical-induced disease ontologies: tools to support NAMs development for next-generation risk assessment
editorial reviewedPhysiological maps (PM) can be defined as a graphical representation of cellular and molecular processes associated to specific organ functions (Vinken et al. 2021). Within the ONTOX project, we designed a total of 6 PMs describing physiological processes in the liver, the kidney and the brain. These PMs are then used as a tool to assess relevant mechanistic coverage and linkage between a specific organ function and a toxicological endpoint. Based on the Disease Maps project (Mazein et al. 2018) pipeline, we developed the first version of
6 PMs describing the following physiological processes: bile secretion & lipid metabolism (liver), vitamin D metabolism & urine composition (kidney), neural tube closure (update of the work of Heusinkveld et al. 2021) & brain development (brain). Our workflow included: (i) data collection from expert curated literature (ii) identification of the relevant biological mechanisms, (iii) screening of online databases (e.g. Wikipathways, Reactome, and KEGG) for previously described pathways, (iv) manual curation and integration of the data into a PM using CellDesigner, and (v) visualization on the MINERVA platform (Hoksza et al. 2019). These qualitative PMs represent an important tool for exploring curated literature, analyzing
networks and benchmarking the development of new adverse outcome pathways (AOPs). These PMs provide the basis for developing quantitative disease ontologies, integrating different layers of pathological and toxicological information, chemical information (drug-induced pathways) and kinetic data. The resulting chemical-induced disease ontologies will provide a multi-layered platform for integration and visualization of such information. The ontologies will contribute to improving understanding of organ/disease related pathways in response to chemicals, visualize omics datasets, develop quantitative methods for computational disease modeling and for predicting toxicity, set up an in vitro & in silico test battery to detect a specific type of toxicity, and develop new animal-free approaches for next generation risk assessment
Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations
While human regulatory risk assessment (RA) still largely relies on animal studies, new approach methodologies (NAMs) based on in vitro, in silico or non-mammalian alternative models are increasingly used to evaluate chemical hazards. Moreover, human epidemiological studies with biomarkers of effect (BoE) also play an invaluable role in identifying health effects associated with chemical exposures. To move towards the next generation risk assessment (NGRA), it is therefore crucial to establish bridges between NAMs and standard approaches, and to establish processes for increasing mechanistically-based biological plausibility in human studies. The Adverse Outcome Pathway (AOP) framework constitutes an important tool to address these needs but, despite a significant increase in knowledge and awareness, the use of AOPs in chemical RA remains limited. The objective of this paper is to address issues related to using AOPs in a regulatory context from various perspectives as it was discussed in a workshop organized within the European Union partnerships HBM4EU and PARC in spring 2022. The paper presents examples where the AOP framework has been proven useful for the human RA process, particularly in hazard prioritization and characterization, in integrated approaches to testing and assessment (IATA), and in the identification and validation of BoE in epidemiological studies. Nevertheless, several limitations were identified that hinder the optimal usability and acceptance of AOPs by the regulatory community including the lack of quantitative information on response-response relationships and of efficient ways to map chemical data (exposure and toxicity) onto AOPs. The paper summarizes suggestions, ongoing initiatives and third-party tools that may help to overcome these obstacles and thus assure better implementation of AOPs in the NGRA
SOC-II-09 First steps for creating an ontology for cognitive function defects for regulatory application
peer reviewe
FIRST STEPS FOR CREATING AN ONTOLOGY FOR COGNITIVE FUNCTION DEFECTS FOR REGULATORY APPLICATION
editorial reviewe
Comprehensive mapping of the AOP-Wiki database: identifying biological and disease gaps
Introduction: The Adverse Outcome Pathway (AOP) concept facilitates rapid hazard assessment for human health risks. AOPs are constantly evolving, their number is growing, and they are referenced in the AOP-Wiki database, which is supported by the OECD. Here, we present a study that aims at identifying well-defined biological areas, as well as gaps within the AOP-Wiki for future research needs. It does not intend to provide a systematic and comprehensive summary of the available literature on AOPs but summarizes and maps biological knowledge and diseases represented by the already developed AOPs (with OECD endorsed status or under validation).Methods: Knowledge from the AOP-Wiki database were extracted and prepared for analysis using a multi-step procedure. An automatic mapping of the existing information on AOPs (i.e., genes/proteins and diseases) was performed using bioinformatics tools (i.e., overrepresentation analysis using Gene Ontology and DisGeNET), allowing both the classification of AOPs and the development of AOP networks (AOPN).Results: AOPs related to diseases of the genitourinary system, neoplasms and developmental anomalies are the most frequently investigated on the AOP-Wiki. An evaluation of the three priority cases (i.e., immunotoxicity and non-genotoxic carcinogenesis, endocrine and metabolic disruption, and developmental and adult neurotoxicity) of the EU-funded PARC project (Partnership for the Risk Assessment of Chemicals) are presented. These were used to highlight under- and over-represented adverse outcomes and to identify and prioritize gaps for further research.Discussion: These results contribute to a more comprehensive understanding of the adverse effects associated with the molecular events in AOPs, and aid in refining risk assessment for stressors and mitigation strategies. Moreover, the FAIRness (i.e., data which meets principles of findability, accessibility, interoperability, and reusability (FAIR)) of the AOPs appears to be an important consideration for further development
Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations.
Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations
While human regulatory risk assessment (RA) still largely relies on animal studies, new approach methodologies (NAMs) based on in vitro, in silico or non-mammalian alternative models are increasingly used to evaluate chemical hazards. Moreover, human epidemiological studies with biomarkers of effect (BoE) also play an invaluable role in identifying health effects associated with chemical exposures. To move towards the next generation risk assessment (NGRA), it is therefore crucial to establish bridges between NAMs and standard approaches, and to establish processes for increasing mechanistically-based biological plausibility in human studies. The Adverse Outcome Pathway (AOP) framework constitutes an important tool to address these needs but, despite a significant increase in knowledge and awareness, the use of AOPs in chemical RA remains limited. The objective of this paper is to address issues related to using AOPs in a regulatory context from various perspectives as it was discussed in a workshop organized within the European Union partnerships HBM4EU and PARC in spring 2022. The paper presents examples where the AOP framework has been proven useful for the human RA process, particularly in hazard prioritization and characterization, in integrated approaches to testing and assessment (IATA), and in the identification and validation of BoE in epidemiological studies. Nevertheless, several limitations were identified that hinder the optimal usability and acceptance of AOPs by the regulatory community including the lack of quantitative information on response-response relationships and of efficient ways to map chemical data (exposure and toxicity) onto AOPs. The paper summarizes suggestions, ongoing initiatives and third-party tools that may help to overcome these obstacles and thus assure better implementation of AOPs in the NGRA